Cargando…

The Impact of the Low Molecular Weight Heparin Tinzaparin on the Sensitization of Cisplatin-Resistant Ovarian Cancers—Preclinical In Vivo Evaluation in Xenograft Tumor Models

Resistance formation of tumors against chemotherapeutics is the major obstacle in clinical cancer therapy. Although low molecular weight heparin (LMWH) is an important component in oncology referring to guideline-based antithrombotic prophylaxis of tumor patients, a potential interference of LMWH wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Mueller, Thomas, Pfankuchen, Daniel Bastian, Wantoch von Rekowski, Kathleen, Schlesinger, Martin, Reipsch, Franziska, Bendas, Gerd
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6154624/
https://www.ncbi.nlm.nih.gov/pubmed/28467373
http://dx.doi.org/10.3390/molecules22050728
_version_ 1783357726966939648
author Mueller, Thomas
Pfankuchen, Daniel Bastian
Wantoch von Rekowski, Kathleen
Schlesinger, Martin
Reipsch, Franziska
Bendas, Gerd
author_facet Mueller, Thomas
Pfankuchen, Daniel Bastian
Wantoch von Rekowski, Kathleen
Schlesinger, Martin
Reipsch, Franziska
Bendas, Gerd
author_sort Mueller, Thomas
collection PubMed
description Resistance formation of tumors against chemotherapeutics is the major obstacle in clinical cancer therapy. Although low molecular weight heparin (LMWH) is an important component in oncology referring to guideline-based antithrombotic prophylaxis of tumor patients, a potential interference of LMWH with chemoresistance is unknown. We have recently shown that LMWH reverses the cisplatin resistance of A2780cis human ovarian cancer cells in vitro. Here we address the question whether this LMWH effect is also valid under in vivo conditions. Therefore, we established tumor xenografts of A2780 and cisplatin resistant A2780cis cells in nude mice and investigated the impact of daily tinzaparin applications (10 mg/kg BW) on anti-tumor activity of cisplatin (6 mg/kg BW, weekly) considering the tumor growth kinetics. Intratumoral platinum accumulation was detected by GF-AAS. Xenografts of A2780 and A2780cis cells strongly differed in cisplatin sensitivity. As an overall consideration, tinzaparin co-treatment affected the response to cisplatin of A2780cis, but not A2780 tumors in the later experimental time range. A subgroup analysis confirmed that initially smaller A2780cis tumors benefit from tinzaparin, but also small A2780 xenografts. Tinzaparin did not affect cisplatin accumulation in A2780cis xenografts, but strongly increased the platinum content in A2780, obviously related to morphological differences in both xenografts. Although we cannot directly confirm a return of A2780cis cisplatin resistance by tinzaparin, as shown in vitro, the present findings give reason to discuss heparin effects on cytostatic drug efficiency for small tumors and warrants further investigation.
format Online
Article
Text
id pubmed-6154624
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-61546242018-11-13 The Impact of the Low Molecular Weight Heparin Tinzaparin on the Sensitization of Cisplatin-Resistant Ovarian Cancers—Preclinical In Vivo Evaluation in Xenograft Tumor Models Mueller, Thomas Pfankuchen, Daniel Bastian Wantoch von Rekowski, Kathleen Schlesinger, Martin Reipsch, Franziska Bendas, Gerd Molecules Article Resistance formation of tumors against chemotherapeutics is the major obstacle in clinical cancer therapy. Although low molecular weight heparin (LMWH) is an important component in oncology referring to guideline-based antithrombotic prophylaxis of tumor patients, a potential interference of LMWH with chemoresistance is unknown. We have recently shown that LMWH reverses the cisplatin resistance of A2780cis human ovarian cancer cells in vitro. Here we address the question whether this LMWH effect is also valid under in vivo conditions. Therefore, we established tumor xenografts of A2780 and cisplatin resistant A2780cis cells in nude mice and investigated the impact of daily tinzaparin applications (10 mg/kg BW) on anti-tumor activity of cisplatin (6 mg/kg BW, weekly) considering the tumor growth kinetics. Intratumoral platinum accumulation was detected by GF-AAS. Xenografts of A2780 and A2780cis cells strongly differed in cisplatin sensitivity. As an overall consideration, tinzaparin co-treatment affected the response to cisplatin of A2780cis, but not A2780 tumors in the later experimental time range. A subgroup analysis confirmed that initially smaller A2780cis tumors benefit from tinzaparin, but also small A2780 xenografts. Tinzaparin did not affect cisplatin accumulation in A2780cis xenografts, but strongly increased the platinum content in A2780, obviously related to morphological differences in both xenografts. Although we cannot directly confirm a return of A2780cis cisplatin resistance by tinzaparin, as shown in vitro, the present findings give reason to discuss heparin effects on cytostatic drug efficiency for small tumors and warrants further investigation. MDPI 2017-05-03 /pmc/articles/PMC6154624/ /pubmed/28467373 http://dx.doi.org/10.3390/molecules22050728 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Mueller, Thomas
Pfankuchen, Daniel Bastian
Wantoch von Rekowski, Kathleen
Schlesinger, Martin
Reipsch, Franziska
Bendas, Gerd
The Impact of the Low Molecular Weight Heparin Tinzaparin on the Sensitization of Cisplatin-Resistant Ovarian Cancers—Preclinical In Vivo Evaluation in Xenograft Tumor Models
title The Impact of the Low Molecular Weight Heparin Tinzaparin on the Sensitization of Cisplatin-Resistant Ovarian Cancers—Preclinical In Vivo Evaluation in Xenograft Tumor Models
title_full The Impact of the Low Molecular Weight Heparin Tinzaparin on the Sensitization of Cisplatin-Resistant Ovarian Cancers—Preclinical In Vivo Evaluation in Xenograft Tumor Models
title_fullStr The Impact of the Low Molecular Weight Heparin Tinzaparin on the Sensitization of Cisplatin-Resistant Ovarian Cancers—Preclinical In Vivo Evaluation in Xenograft Tumor Models
title_full_unstemmed The Impact of the Low Molecular Weight Heparin Tinzaparin on the Sensitization of Cisplatin-Resistant Ovarian Cancers—Preclinical In Vivo Evaluation in Xenograft Tumor Models
title_short The Impact of the Low Molecular Weight Heparin Tinzaparin on the Sensitization of Cisplatin-Resistant Ovarian Cancers—Preclinical In Vivo Evaluation in Xenograft Tumor Models
title_sort impact of the low molecular weight heparin tinzaparin on the sensitization of cisplatin-resistant ovarian cancers—preclinical in vivo evaluation in xenograft tumor models
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6154624/
https://www.ncbi.nlm.nih.gov/pubmed/28467373
http://dx.doi.org/10.3390/molecules22050728
work_keys_str_mv AT muellerthomas theimpactofthelowmolecularweightheparintinzaparinonthesensitizationofcisplatinresistantovariancancerspreclinicalinvivoevaluationinxenografttumormodels
AT pfankuchendanielbastian theimpactofthelowmolecularweightheparintinzaparinonthesensitizationofcisplatinresistantovariancancerspreclinicalinvivoevaluationinxenografttumormodels
AT wantochvonrekowskikathleen theimpactofthelowmolecularweightheparintinzaparinonthesensitizationofcisplatinresistantovariancancerspreclinicalinvivoevaluationinxenografttumormodels
AT schlesingermartin theimpactofthelowmolecularweightheparintinzaparinonthesensitizationofcisplatinresistantovariancancerspreclinicalinvivoevaluationinxenografttumormodels
AT reipschfranziska theimpactofthelowmolecularweightheparintinzaparinonthesensitizationofcisplatinresistantovariancancerspreclinicalinvivoevaluationinxenografttumormodels
AT bendasgerd theimpactofthelowmolecularweightheparintinzaparinonthesensitizationofcisplatinresistantovariancancerspreclinicalinvivoevaluationinxenografttumormodels
AT muellerthomas impactofthelowmolecularweightheparintinzaparinonthesensitizationofcisplatinresistantovariancancerspreclinicalinvivoevaluationinxenografttumormodels
AT pfankuchendanielbastian impactofthelowmolecularweightheparintinzaparinonthesensitizationofcisplatinresistantovariancancerspreclinicalinvivoevaluationinxenografttumormodels
AT wantochvonrekowskikathleen impactofthelowmolecularweightheparintinzaparinonthesensitizationofcisplatinresistantovariancancerspreclinicalinvivoevaluationinxenografttumormodels
AT schlesingermartin impactofthelowmolecularweightheparintinzaparinonthesensitizationofcisplatinresistantovariancancerspreclinicalinvivoevaluationinxenografttumormodels
AT reipschfranziska impactofthelowmolecularweightheparintinzaparinonthesensitizationofcisplatinresistantovariancancerspreclinicalinvivoevaluationinxenografttumormodels
AT bendasgerd impactofthelowmolecularweightheparintinzaparinonthesensitizationofcisplatinresistantovariancancerspreclinicalinvivoevaluationinxenografttumormodels